Initiates Coverage on Nabriva Therapeutics (NASDAQ:NBRV)

Research analysts at started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVGet Rating) in a report released on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, Northland Securities raised their target price on shares of Nabriva Therapeutics from $50.00 to $450.00 and gave the stock an “outperform” rating in a report on Friday.

Nabriva Therapeutics Stock Performance

NASDAQ:NBRV opened at $3.82 on Monday. Nabriva Therapeutics has a twelve month low of $3.75 and a twelve month high of $35.00. The company has a current ratio of 2.81, a quick ratio of 2.01 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $6.35 and a 200-day moving average of $7.05. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -0.18 and a beta of 1.46.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last posted its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported ($4.50) earnings per share for the quarter, beating the consensus estimate of ($5.00) by $0.50. Nabriva Therapeutics had a negative net margin of 131.91% and a negative return on equity of 95.18%. The company had revenue of $9.19 million during the quarter, compared to analyst estimates of $8.53 million. Analysts forecast that Nabriva Therapeutics will post -17 earnings per share for the current fiscal year.

Institutional Trading of Nabriva Therapeutics

Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its position in Nabriva Therapeutics by 102.1% during the second quarter. Renaissance Technologies LLC now owns 795,938 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 402,144 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in Nabriva Therapeutics during the first quarter valued at approximately $179,000. Finally, GSA Capital Partners LLP bought a new position in Nabriva Therapeutics during the fourth quarter valued at approximately $214,000. 0.53% of the stock is owned by hedge funds and other institutional investors.

About Nabriva Therapeutics

(Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

Further Reading

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.